Conference Coverage
Latest News
Barzolvolimab Effective for CSU in Phase 2 Study
Barzolvolimab is an anti-KIT monoclonal antibody that inhibits the activation of and depletes mast cells.
Latest News
Nemolizumab Benefits for Atopic Dermatitis Maintained in Long-Term Follow-Up Study
Nemolizumab was associated with “ongoing clinically meaningful improvements in itch, skin lesions, and sleep disturbance,” reported Dr. Diamant...
Latest News
Lichen Planus Responds to Treatment with Topical Ruxolitinib in Phase 2 Study
Ruxolitinib cream twice daily resulted in “significant improvements in cutaneous lichen planus disease severity vs vehicle” after 16 weeks of...
Latest News
Study Finds No Increased MACE Risk for JAK Inhibitors in Patients With Atopic Dermatitis
The analysis looked at treatment with the upadacitinib and abrocitinib (Cibinqo), both approved for treating AD in...
Latest News
Topical JAK Inhibitor Effective for Hand Eczema, Two Studies Suggest
Delgocitinib cream, currently under FDA review for chronic hand eczema, was recently approved in Europe for treating adults with moderate to...
Conference Coverage
Does Bezlotoxumab Boost FMT Efficacy in IBD Patients With Recurrent CDI?
Patients with IBD have a prevalence of C difficile infection that is 2.5- to 8-fold higher than in peers without IBD.
Feature
What Matters Most for Young Patients With CRC: Survey Highlights Top Concerns
Cancer is ‘impacting younger people who are in important developmental stages of their lives.’
Conference Coverage
Do Patients on Anti-Obesity Drugs Decrease Alcohol Use?
This new study is the first to examine the relationship with different classes of anti-obesity medications and to quantify the amount of alcohol...
Conference Coverage
Angiotensin Receptor Blockers May Lead to Worse Outcomes in Celiac Disease
The association may be related to the similar pathophysiology between ARB-associated enteropathy and celiac disease.
Conference Coverage
Shorter H pylori Treatment With Vonoprazan Shows Better Results
The triple therapy regimen with vonoprazan was generally better tolerated than the 14-day omeprazole-based regimen.
Latest News
Knowledge Gaps About Obesity Medicine Seen in Primary Care
“The treatment of obesity as a disease, especially with some of the newer medical treatments, is not standard of care and practiced widely.”